Literature DB >> 8805892

The application of EMLA and glyceryl trinitrate ointment prior to venepuncture.

A Michael1, M Andrew.   

Abstract

The efficacy of EMLA cream combined with glyceryl trinitrate (GTN) ointment was assessed by a double-blind prospective study. Adult female patients were randomly allocated to receive either EMLA 1 ml or 2 ml combined with GTN 2 mg, or EMLA 2 ml only. The difference in pain scores between the three groups was not statistically significant. When GTN was used with EMLA, the quality of the veins was superior and aided intravenous cannulation. There were no significant side-effects. It is concluded that if GTN is used with EMLA, the dose of EMLA can be reduced and intravenous cannulation is technically easier compared with EMLA alone.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8805892     DOI: 10.1177/0310057X9602400310

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  5 in total

Review 1.  Methods of obtaining peripheral venous access in difficult situations.

Authors:  D Mbamalu; A Banerjee
Journal:  Postgrad Med J       Date:  1999-08       Impact factor: 2.401

2.  Intravenous therapy.

Authors:  C Waitt; P Waitt; M Pirmohamed
Journal:  Postgrad Med J       Date:  2004-01       Impact factor: 2.401

Review 3.  Pharmacological management of pain and anxiety during emergency procedures in children.

Authors:  R M Kennedy; J D Luhmann
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

4.  Local warming and insertion of peripheral venous cannulas: single blinded prospective randomised controlled trial and single blinded randomised crossover trial.

Authors:  Rainer Lenhardt; Tanja Seybold; Oliver Kimberger; Brigitte Stoiser; Daniel I Sessler
Journal:  BMJ       Date:  2002-08-24

5.  Local anaesthesia for venous cannulation and arterial blood gas sampling: are doctors using it?

Authors:  Daniel M Sado; Charles D Deakin
Journal:  J R Soc Med       Date:  2005-04       Impact factor: 18.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.